Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moxidectin QT Interval Study in Healthy Volunteers
NCT03012828Phase 1Completed
- Sponsor
- Medicines Development for Global Health
- Start
- Jan 2017
- Primary completion
- Mar 2017
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of moxidectin in onchocerciasis (6 arms), sponsored by Medicines Development for Global Health. Primary endpoint: Mean Change From Baseline in QTc Interval (Corrected by Fridericia's Formula, dQTcF) Associated With Plasma Moxidectin Concentrations at 72 hours. Started Jan 2017; status: completed.
02
Drugs
moxidectin
03
Conditions
onchocerciasis
Beyond the preview
Go deeper on NCT03012828.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03012828.